Jon Congleton, serving as the Chief Executive Officer of Mineralys Therapeutics, Inc. (NASDAQ: MLYS), has executed a significant divestment of company equity. On June 30, 2026, Congleton sold a total of 75,000 shares of the company's common stock. The aggregate value of these transactions reached approximately $1,960,601. The execution of these sales occurred within a price range of $25.9432 to $26.8174 per share.
The disposition of shares was structured in two distinct blocks. Initially, Congleton disposed of 58,000 shares at a weighted-average price of $25.9432. Following this initial block, he sold an additional 17,000 shares at a weighted-average price of $26.8174. These transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was formally adopted on December 30, 2025. This pre-arranged plan provides a structured mechanism for the sale of securities.
Following the completion of these transactions, Mr. Congleton's direct ownership of Mineralys Therapeutics common stock stands at 614,321 shares. The insider sale activity coincides with the company's stock trading at $26.99, a level that represents an increase of nearly 100% over the past year. Market analysis indicates that the stock may currently appear overvalued relative to its calculated Fair Value. Analysts have established price targets for the stock ranging between $30 and $56.
Concurrent with executive trading activity, Mineralys Therapeutics has advanced significant corporate financial strategies. The company recently announced the pricing of an underwritten public offering comprising 5,660,378 shares of common stock. These shares were priced at $26.50 per share, with the objective of raising approximately $150 million in gross proceeds. Furthermore, the company has initiated a series of financial transactions totaling $750 million aimed at repurchasing royalty obligations and strengthening its balance sheet. A critical component of this strategy involves an upfront payment of $200 million to Tanabe Pharma Corporation. This agreement includes the potential for up to $100 million in additional payments contingent upon the achievement of specific commercial milestones. The primary objective of this arrangement is to eliminate future royalty payments associated with lorundrostat.
Market sentiment regarding the company is reflected in recent analyst actions. Jefferies has reiterated a Hold rating on Mineralys stock, maintaining a $30.00 price target. This assessment considers the potential for acquisition as the company's new drug application undergoes FDA review. Conversely, H.C. Wainwright has reiterated a Buy rating with a $30.00 price target, following the presentation of post hoc analysis from the company's pivotal Launch-HTN trial. The analysis, presented at the European Meeting on Hypertension and Cardiovascular Protection, focused on lorundrostat, which is being developed for uncontrolled or resistant hypertension.
Mineralys has also presented clinical data from the Phase 3 Launch-HTN trial, which evaluated lorundrostat in patients with uncontrolled or resistant hypertension. This population includes individuals with chronic kidney disease. Notably, a significant portion of these patients were already on multiple anti-hypertensive medications at the start of the trial. These developments underscore the company's efforts to advance its therapeutic offerings while managing its financial strategies.